94-18260. Revco D.S., Inc.; Proposed Consent Agreement With Analysis to Aid Public Comment  

  • [Federal Register Volume 59, Number 143 (Wednesday, July 27, 1994)]
    [Unknown Section]
    [Page 0]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 94-18260]
    
    
    [[Page Unknown]]
    
    [Federal Register: July 27, 1994]
    
    
    -----------------------------------------------------------------------
    
    FEDERAL TRADE COMMISSION
    [File No. 941 0075]
    
     
    
    Revco D.S., Inc.; Proposed Consent Agreement With Analysis to Aid 
    Public Comment
    
    AGENCY: Federal Trade Commission.
    
    ACTION: Proposed consent agreement.
    
    -----------------------------------------------------------------------
    
    SUMMARY: In settlement of alleged violations of federal law prohibiting 
    unfair acts and practices and unfair methods of competition, this 
    consent agreement, accepted subject to final Commission approval, would 
    require, among other things, a Ohio-based drugstore chain to divest, 
    within one year of the order, to a Commission approved acquirer, all 
    assets related to the retail sale of prescription drugs in either the 
    respondent's store or in the acquired Hook-SupeRx (HSI) retail store in 
    each of three geographic areas, and to complete the divestiture within 
    one year. If not complete in that period of time, the order would 
    require the respondent to consent to the appointment of a trustee to 
    divest the assets. In addition, the proposed consent agreement would 
    require the respondent to obtain prior Commission approval, for ten 
    years, before acquiring any similar business interest in any of the 
    three specified towns.
    
    DATES: Comments must be received on or before September 26, 1994.
    
    ADDRESSES: Comments should be directed to FTC/Office of the Secretary, 
    Room 159, 6th St. and Pa. Ave., N.W., Washington, DC. 20580.
    
    FOR FURTHER INFORMATION CONTACT:Laura Wilkinson or Ann Malester, FTC/S-
    2224, Washington, DC 20580. (202) 226-2830 or 326-2682.
    
    SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal 
    Trade Commission Act, 38 Stat. 721, 15 U.S.C. 46 and Section 2.34 of 
    the Commission's Rules of Practice (16 CFR 2.34), notice is hereby 
    given that the following consent agreement containing a consent order 
    to divest, having been filed with and accepted, subject to final 
    approval, by the Commission, has been placed on the public record for a 
    period of sixty (60) days. Public comment is invited. Such comments or 
    views will be considered by the Commission and will be available for 
    inspection and copying at its principal office in accordance with 
    Section 4.9(b)(6)(ii) of the Commission's Rules of Practice (16 CFR 
    4.9(b)(6)(ii)).
    
        In the matter of Revco D.S., Inc., a corporation. File No. 941-
    0075.
    
    Agreement Containing Consent Order
    
        The Federal Trade Commission (``Commission'') having initiated an 
    investigation of the proposed acquisition of all of the voting stock of 
    Hook SupeRx, Inc. (``HSI''), by Revco D.S., Inc. (``Revco''), and it is 
    now appearing that Revco, hereinafter sometimes referred to as 
    ``Proposed Respondent,'' is willing to enter into an agreement 
    containing an order (``Agreement'') to divest certain assets, and to 
    cease and desist from making certain acquisitions, and providing for 
    certain other relief:
        It is hereby agreed by and between Proposed Respondent, by its duty 
    authorized officers and attorneys, and counsel for the Commission that:
        1. Proposed Respondent Revco is a corporation organized, existing, 
    and doing business under and by the virtue of the laws of the State of 
    Delaware with its office and principal place of business located at 
    1925 Enterprise Parkway, Twinsburg, Ohio 44087.
        2. Proposed Respondent admits all the jurisdictional facts set 
    forth in the draft of complaint here attached.
        3. Proposed Respondent waives:
        a. any further procedural steps;
        b. the requirement that the Commission's decision contain a 
    statement of findings of fact and conclusions of law;
        c. all rights to seek judicial review or otherwise to challenge or 
    contest the validity of the order entered pursuant to this agreement; 
    and
        d. any claim under the Equal Access to Justice Act.
        4. This Agreement shall not become part of the public record of the 
    proceeding unless and until it is accepted by the Commission. If this 
    Agreement is accepted by the Commission it, together with the draft of 
    complaint contemplated thereby, will be placed on the public record for 
    a period of sixty (60) days and information in respect thereto publicly 
    released. The Commission thereafter may either withdraw its acceptance 
    of this agreement and so notify the Proposed Respondent, in which event 
    it will take such action as it may consider appropriate, or issue and 
    serve its complaint (in such form as the circumstances may require) and 
    decision, in disposition of the proceeding.
        5. This Agreement is for settlement purposes only and does not 
    constitute an admission by Proposed Respondent that the law has been 
    violated as alleged in the draft of complaint here attached, or that 
    the facts as alleged in the draft complaint, other than the 
    jurisdictional facts, are true.
        6. This Agreement contemplates that, if it is accepted by the 
    Commission, and if such acceptance is not subsequently withdrawn by the 
    Commission pursuant to the provisions of Section 2.34 of the 
    Commission's Rules, the Commission may, without further notice to the 
    Proposed Respondent, (1) issue its complaint corresponding in form and 
    substance with the draft of complaint here attached and its decision 
    containing the following Order to divest and to cease and desist in 
    disposition of the proceeding, and (2) make information public with 
    respect thereto. When so entered, the Order shall have the same force 
    and effect and may be altered, modified, or set aside in the same 
    manner and within the same time provided by statute for other orders. 
    The Order shall become final upon service. Delivery by the United 
    States Postal Service of the complaint and decision containing the 
    agreed-to Order to Proposed Respondent's address as stated in this 
    Agreement shall constitute service. Proposed Respondent waives any 
    right it may have to any other manner of services. The complaint may be 
    used in construing the terms of the Order, and no agreement, 
    understanding, representation, or interpretation not contained in the 
    Order or the agreement may be used to vary or contradict the terms of 
    the Order.
        7. Proposed Respondent has read the proposed Complaint and Order 
    contemplated hereby. Proposed Respondent understands that once the 
    Order has been issued, it will be required to file one or more 
    compliance reports showing that it has fully complied with the Order. 
    Proposed Respondent further understands that it may be liable for civil 
    penalties in the amount provided by law for each violation of the Order 
    after it becomes final.
    
    Order
    
    I
        It is ordered That, as used in this Order, the following 
    definitions shall apply:
        A. ``Revco'' means Revco D.S., Inc., its predecessors, 
    subsidiaries, divisions, groups and affiliates controlled by Revco, and 
    their respective directors, officers, employees, agents, 
    representatives, and their respective successors and assigns.
        B. ``Commission'' means the Federal Trade Commission.
        C. ``Acquisition'' means the acquisition of all the voting stock of 
    Hook-SupeRx, Inc. (``HSI`'') by Respondent Revco.
        D. ``Acquirer'' means the party or parties to whom Respondent Revco 
    divests the assets herein ordered to be divested.
        E. ``Prescription drugs'' means ethical drugs available at retail 
    only by prescription.
        F. ``HSI Pharmacy Business'' means HSI's business of selling 
    prescription drugs at any of the retail stores listed in Paragraph 
    I.(J). of this Order, but does not include HSI's business of selling 
    other products in those retail stores.
        G. ``HSI Pharmacy Assets'' means all assets constituting the HSI 
    Pharmacy Business, excluding those assets pertaining to the Hook, 
    SupeRx, and Brooks trade names, trade dress, trade marks and service 
    marks, and to Revco's proprietary point of sale equipment or its 
    PAL system, and including but not limited to:
        1. Leases, at the Acquirer's option;
        2. zoning approvals and registrations, at the Acquirer's option;
        3. books, records, manuals, and operations reports relating to the 
    HSI Pharmacy Business, but only if the divestiture is to an Acquirer 
    that does not already operate a pharmacy in any location;
        4. inventory instruction, or, at the Acquirer's option, lists of 
    stock keeping units (``SKUs''), i.e., all forms, package sizes and 
    other units in which prescription drugs are sold and which are used in 
    records of sales and inventories;
        5. lists of all prescription drug customers, including but not 
    limited to third party insurers, including all files of names, 
    addresses, and telephone numbers of the individual customer contacts, 
    the unit and dollar amounts of sales, by product, to each customer, and 
    store profit and loss statement(s);
        6. all names and addresses of prescription drug manufacturers and 
    distributors that supply or have supplied HSI within the six months 
    preceding the date this Order becomes final; and
        7. goodwill, tangible and intangible, utilized in the sale of 
    prescription drugs.
        H. ``Revco Pharmacy Business'' means Revco's business of selling 
    prescription drugs at any of the retail stores listed in Paragraph 
    I.(J). of this Order, but does not include Revco's business of selling 
    other products in those retail stores.
        I. ``Revco Pharmacy Assets'' means all assets constituting the 
    Revco Pharmacy Business, excluding those assets pertaining to the Revco 
    trade names, trade dress, trade marks and service marks, and to Revco's 
    proprietary point of sale equipment or its PAL system, and 
    including but not limited to:
        1. Leases, at the Acquirer's option;
        2. zoning approvals and registrations, at the Acquirer's option;
        3. books, records, manuals, and operations reports, relating to the 
    Revco Pharmacy Business, but only if the divestiture is to an Acquirer 
    that does not already operate a pharmacy in any location;
        4. inventory instruction, or, at the Acquirer's option, lists of 
    SKUs, i.e., all forms, package sizes and other units in which 
    prescription drugs are sold and which are used in records of sales and 
    inventories;
        5. lists of all prescription drug customers, including but not 
    limited to third party insurers, including all files of names, 
    addresses, and telephone numbers of the individual customer contacts, 
    the unit and dollar amounts of sales, by product, to each customer, and 
    store profit and loss statement(s);
        6. all names and addresses of prescription drug manufacturers and 
    distributors that supply or have supplied Revco within the six months 
    preceding the date this Order becomes final; and
        7. goodwill, tangible and intangible, utilized in the sale of 
    prescription drugs.
        J. ``Assets To Be Divested'' means either the HSI Pharmacy Assets 
    or the Revco Pharmacy Assets constituting the HSI Pharmacy Business or 
    the Revco Pharmacy Business in the following cities or towns:
        1. Covington, Virginia;
        2. Marion, Virginia; and
        3. Radford, Virginia.
        K. ``Competitiveness, viability and marketability'' of the Assets 
    To Be Divested mean that Respondent shall continue the operation of the 
    Assets To Be Divested in the ordinary course of business without 
    material change or alteration that would adversely affect the value or 
    goodwill of the Assets To Be Divested.
    II
        It is further ordered That:
        A. Respondent shall divest, absolutely and in good faith, within 
    twelve (12) months of the date this Order becomes final, the Assets To 
    Be Divested.
        B. Respondent shall divest the Assets To Be Divested only to an 
    acquirer or acquirers that receive the prior approval of the Commission 
    and only in a manner that receives the prior approval of the 
    Commission. The purpose of the divestiture of the Assets To Be Divested 
    is to ensure the continued use of the Assets To Be Divested as ongoing 
    viable pharmacies engaged in the same businesses in which the Assets To 
    Be Divested are presently employed and to remedy the lessening of 
    competition resulting from the acquisition as alleged in the 
    Commission's complaint.
        C. Pending divestiture of the Assets To Be Divested, Respondent 
    shall take such actions as are necessary to maintain the 
    competitiveness, viability and marketability of the Assets To Be 
    Divested and to prevent the destruction, removal, wasting, 
    deterioration, or impairment of any Assets To Be Divested except for 
    ordinary wear and tear.
        D. If a divestiture includes a lease of physical space, and if 
    pursuant to that lease Respondent through default of the lease or 
    otherwise regains possession of the space, Respondent must notify the 
    Commission of such repossession within thirty (30) days and must 
    redivest such assets or interest pursuant to Paragraph II of this Order 
    within six (6) months of such repossession. If Respondent has not 
    redivested such assets or interest pursuant to Paragraph II of this 
    Order within six (6) months of such repossession, the provisions of 
    Paragraph III shall apply to these assets.
    III
        It is further ordered That:
        A. If Respondent has not divested, absolutely and in good faith and 
    with the Commission's prior approval, the Assets To Be Divested within 
    twelve (12) months of the date this Order becomes final, the Commission 
    may appoint a trustee to divest the Assets To Be Divested. In the event 
    the Commission or the Attorney General brings an action pursuant to 
    Sec. 5(l) of the Federal Trade Commission Act, 15 U.S.C. Sec. 45(l), or 
    any other statute enforced by the Commission, Respondent shall consent 
    to the appointment of a trustee in such action. Neither the appointment 
    of a trustee nor a decision not to appoint a trustee under this 
    Paragraph shall preclude the Commission or the Attorney General from 
    seeking civil penalties or any other relief available to it, including 
    a court-appointed trustee, pursuant to Sec. 5(l) of the Federal Trade 
    Commission Act, or any other statute enforced by the Commission, for 
    any failure by Respondent to comply with this Order.
        B. If a trustee is appointed by the Commission or a court pursuant 
    to Paragraph III.A. of this Order, Respondent shall consent to the 
    following terms and conditions regarding the trustee's powers, duties, 
    authority, and responsibilities:
        1. The Commission shall select the trustee, subject to the consent 
    of Respondent, which consent shall not be unreasonably withheld. The 
    trustee shall be a person with experience and expertise in acquisitions 
    and divestitures. If Respondent has not opposed, in writing, including 
    the reasons for opposing, the selection of any proposed trustee within 
    ten (10) days after notice by the staff of the Commission to Respondent 
    of the identity of any proposed trustee, Respondent shall be deemed to 
    have consented to the selection of the proposed trustee.
        2. Subject to the prior approval of the Commission, the trustee 
    shall have the exclusive power and authority to divest the Assets To Be 
    Divested.
        3. Within ten (10) days after appointment of the trustee, 
    Respondent shall execute a trust agreement that, subject to the prior 
    approval of the Commission and, in the case of a court-appointed 
    trustee, of the court, transfers to the trustee all rights and powers 
    necessary to permit the trustee to effect the divestiture required by 
    this Order.
        4. The trustee shall have twelve (12) months from the date the 
    Commission approves the trust agreement described in Paragraph III.B.3 
    to accomplish the divestiture, which shall be subject to the prior 
    approval of the Commission. If, however, at the end of the twelve-month 
    period the trustee has submitted a plan of divestiture or believes that 
    divestiture can be achieved within a reasonable time, the divestiture 
    period may be extended by the Commission, or in the case of a court-
    appointed trustee by the court.
        5. The trustee shall have full and complete access to the 
    personnel, books, records, and facilities related to the Assets To Be 
    Divested, or to any other relevant information, as the trustee may 
    reasonably request. Respondent shall develop such financial or other 
    information as such trustee may reasonably request and shall cooperate 
    with the trustee. Respondent shall take no action to interfere with or 
    impede the trustee's accomplishment of the divestiture. Any delays in 
    divestiture caused by Respondent shall extend the time for divestiture 
    under this Paragraph in an amount equal to the delay, as determined by 
    the Commission or, for a court-appointed trustee, by the court.
        6. The trustee shall use his or her best efforts to negotiate the 
    most favorable price and terms available in each contract that is 
    submitted to the Commission subject to Respondent's absolute and 
    unconditional obligation to divest at no minimum price. The divestiture 
    shall be made in the manner and to the acquirer or acquirers as set out 
    in Paragraph II of this Order. Provided, however, if the trustee 
    receives bona fide offers from more than one acquirer, and if the 
    Commission determines to approve more than one such acquirer, the 
    trustee shall divest to the acquirer or acquirers selected by 
    Respondent from among those approved by the Commission.
        7. The trustee shall serve, without bond or other security, at the 
    cost and expense of Respondent, on such reasonable and customary terms 
    and conditions as the Commission or a court may set. The trustee shall 
    have authority to employ, at the cost and expense of Respondent, such 
    consultants, accountants, attorneys, investment bankers, business 
    brokers, appraisers, and other representatives and assistants as are 
    reasonably necessary to carry out the trustee's duties and 
    responsibilities. The trustee shall account for all monies derived from 
    the divestiture and all expenses incurred. After approval by the 
    Commission and, in the case of a court-appointed trustee, by the court, 
    of the account of the trustee, including fees for his or her services, 
    all remaining monies shall be paid at the direction of Respondent and 
    the trustee's power shall be terminated. The trustee's compensation 
    shall be based at least in significant part on a commission arrangement 
    contingent on the trustee's divesting the Assets To Be Divested.
        8. Respondent shall indemnify the trustee and hold the trustee 
    harmless against any losses, claims, damages, liabilities, or expenses 
    arising out of, or in connection with, the performance of the trustee's 
    duties, and Respondent shall either defend against such claims or pay 
    the trustee's expenses, including all reasonable fees of counsel and 
    other expenses incurred in connection with the preparation for, or 
    defense of any such claim, whether or not resulting in any liability, 
    except to the extent that such liabilities, losses, damages, claims, or 
    expenses result from misfeasance, gross negligence, willful or wanton 
    acts, or bad faith by the trustee.
        9. If the trustee ceases to act or fails to act diligently, a 
    substitute trustee shall be appointed in the same manner as provided in 
    Paragraph III.A. of this Order.
        10. The Commission or, in the case of a court-appointed trustee, 
    the court, may on its own initiative or at the request of the trustee 
    issue such additional orders or directions as may be necessary or 
    appropriate to accomplish the divestiture required by this Order.
        11. The trustee shall have no obligation or authority to operate or 
    maintain the Assets To Be Divested.
        12. The trustee shall report in writing to Respondent and to the 
    Commission every sixty (60) days concerning the trustee's efforts to 
    accomplish divestiture.
    IV
        It is further ordered That, for a period of ten (10) years from the 
    date this Order becomes final, Respondent shall not, without the prior 
    approval of the Commission, directly or indirectly, through 
    subsidiaries, partnerships, or otherwise: (A) Acquire any stock, share 
    capital, equity, leasehold or other interest in any concern, corporate 
    or non-corporate, presently engaged in, or within the six months 
    preceding such acquisition engaged in, the business of selling 
    prescription drugs at retail stores located in any of the cities or 
    towns listed in Paragraph I. (J). of this Order; or (B) Acquire any 
    assets used for, or previously used for (and still suitable for use 
    for), the business of selling prescription drugs at retail stores 
    located in any of the cities or towns listed in Paragraph I.(J). of 
    this Order from any concern, corporate or non-corporate, presently 
    engaged in or within the six months preceding such acquisition engaged 
    in, the business of selling prescription drugs at retail stores located 
    in any of the cities or towns listed in Paragraph I.(J). of this Order. 
    Provided, however, that these prohibitions shall not relate to the 
    construction of new facilities.
    V
        It is further ordered That:
        A. Within sixty (60) days after the date this Order becomes final 
    and every sixty (60) days thereafter until Respondent has fully 
    complied with the provisions of Paragraphs II. and III. of this Order, 
    Respondent shall submit to the Commission a verified written report 
    setting forth in detail the manner and form in which it intends to 
    comply, is complying, and has complied with those provisions. 
    Respondent shall include in its compliance reports, among other things 
    that are required from time to time, a full description of the efforts 
    being made to comply with Paragraphs II and III of the Order, including 
    a description of all substantive contacts or negotiations for the 
    divestiture and the identity of all parties contacted. Respondent also 
    shall include in its compliance reports copies of all written 
    communications to and from such parties, all internal memoranda, and 
    all reports and recommendations concerning divestiture.
        B. One (1) year from the date this Order becomes final, annually 
    thereafter for the next nine (9) years on the anniversary of the date 
    this Order became final, and at such other times as the Commission may 
    require, Respondent shall file a verified written report with the 
    Commission setting forth in detail the manner and form in which it has 
    complied and is complying with Paragraph IV. of this Order.
    VI
        It is further ordered That Respondent shall notify the Commission 
    at least thirty (30) days prior to any proposed change in the corporate 
    respondent such as dissolution, assignment, sale resulting in the 
    emergence of a successor corporation, or the creation or dissolution of 
    subsidiaries or any other change in the corporation that may affect 
    compliance obligations arising out of the Order.
    VII
        It is further ordered That, for the purpose of determining or 
    securing compliance with this Order, Respondent shall permit any duly 
    authorized representative of the Commission:
        A. Access, during office hours and in the presence of counsel, to 
    inspect and copy all books, ledgers, accounts, correspondence, 
    memoranda and other records and documents in the possession or under 
    the control of Respondent relating to any matters contained in this 
    consent order; and
        B. Upon five (5) days notice to Respondent, and without restraint 
    or interference from it, to interview officers, directors, or employees 
    of Respondent, who may have counsel present, regarding such matters.
    
    Analysis of Proposed Consent Order to Aid Public Comment
    
        The Federal Trade Commission (``Commission'') has accepted 
    provisionally an agreement containing a proposed Consent Order from 
    Revco D.S., Inc. (``Revco'') under which Revco would divest pharmacy 
    assets in three (3) geographic locations where it faces limited 
    competition. Revco operates the Revco chain of drug stores.
        The proposed Consent Order has been placed on the public record for 
    sixty (60) days for reception of comments by interested persons. 
    Comments received during this period will become part of the public 
    record. After sixty (60) days, the Commission will again review the 
    agreement and the comments received and will decide whether it should 
    withdraw from the agreement or make final the agreement's proposed 
    Order.
        On March 31, 1994 Revco and Hook-SupeRx, Inc. (``HSI'') executed an 
    Agreement and Plan or Merger providing for the acquisition by Revco of 
    all of the voting securities of HSI. The proposed complaint alleges 
    that the proposed acquisition, if consummated, would constitute a 
    violation of Section 7 of the Clayton Act, as amended, 15 U.S.C. 
    Sec. 18, and Section 5 of the FTC Act, as amended, 15 U.S.C. Sec. 45, 
    in the market for the sale of prescription drugs in retail stores in 
    the following towns: Covington, Virginia; Marion, Virginia; and 
    Radford, Virginia (hereinafter ``relevant geographic area''). The 
    proposed Consent Order would remedy the alleged violation by 
    maintaining the current number of competitors in the relevant 
    geographic areas where Revco and HSI are direct competitors and where 
    they face limited competition.
        The proposed Consent Order provides that within one (1) year of the 
    Order becoming final, Revco shall divest all assets related to the 
    retail sale of prescription drugs in Revco or HSI retail stores in the 
    relevant geographic areas. The divestiture of the Revco or HSI pharmacy 
    business in the relevant geographic areas shall be made only to an 
    acquirer or acquirers that receive prior approval of the Commission and 
    only in a manner that receives the prior approval of the Commission. 
    The assets shall be divested to an eligible acquirer or acquirers that 
    will operate a pharmacy business in the relevant geographic areas. 
    Eligible acquirers in each relevant geographic area include, but are 
    not limited to: owners of retail stores that currently do not operate a 
    pharmacy in that relevant geographic area; persons previously employed 
    by Revco or HSI; or persons who will open a new retail store. In the 
    event that Revco has not divested the Revco or HSI pharmacy assets in 
    the relevant areas in one (1) year, the proposed Consent Order provides 
    that Revco shall consent to the appointment by the Commission of a 
    trustee to divest the pharmacy assets.
        Under the provisions of the Consent Order, Revco is also required 
    to provide to the Commission a report of its compliance with the 
    divestiture provisions of the Order within sixty (60) days following 
    the date this Order becomes final, and every sixty (60) days thereafter 
    until Revco has completely divested its interest in assets related to 
    the retail sale of prescription drugs in the relevant geographic areas. 
    The proposed Order will also prohibit Revco, for a period of ten (10) 
    years, from acquiring, without Federal Trade Commission approval, any 
    stock in any concern engaged in the business of selling prescription 
    drugs at retail in the relevant geographic areas or any assets used for 
    the business of selling prescription drugs at retail in the relevant 
    geographic areas.
        One year from the date the Order becomes final and annually 
    thereafter for nine (9) years, Revco will be required to provide to the 
    Commission a report of its compliance with the Consent Order. The 
    Consent Order also requires Revco to notify the Commission at least 
    thirty (30) day prior to any change in the structure of Revco resulting 
    in the emergence of a successor.
        The purpose of this analysis is to facilitate public comment on the 
    proposed Order, and it is not intended to constitute an official 
    interpretation of the agreement and proposed Order or to modify in any 
    way their terms.
    Donald S. Clark,
    Secretary.
    [FR Doc. 94-18260 Filed 7-26-94; 8:45 am]
    BILLING CODE 6750-01-M
    
    
    

Document Information

Published:
07/27/1994
Department:
Federal Trade Commission
Entry Type:
Uncategorized Document
Action:
Proposed consent agreement.
Document Number:
94-18260
Dates:
Comments must be received on or before September 26, 1994.
Pages:
0-0 (1 pages)
Docket Numbers:
Federal Register: July 27, 1994, File No. 941 0075